Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA) Stock Price & Analysis


AKBA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.24 - $2.34
Previous Close$0.6
Average Volume (3M)2.27M
Market Cap
Enterprise Value$120.92M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.2
May 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding184,248,045
10 Day Avg. Volume1,071,309
30 Day Avg. Volume2,271,182
Standard Deviation0.28
Financial Highlights & Ratios
Price to Book (P/B)-1.00
Price to Sales (P/S)0.38
Price to Cash Flow (P/CF)10.50
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.83
Price Target Upside110.97% Upside
Rating ConsensusHold
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.24 and its highest was $2.34 in the past 12 months.
    What is Akebia Therapeutics’s market cap?
    Currently, no data Available
    When is Akebia Therapeutics’s upcoming earnings report date?
    Akebia Therapeutics’s upcoming earnings report date is May 08, 2023 which is in 40 days.
      How were Akebia Therapeutics’s earnings last quarter?
      Akebia Therapeutics released its earnings results on Mar 09, 2023. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.183 by $0.143.
        Is Akebia Therapeutics overvalued?
        According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Akebia Therapeutics pay dividends?
          Akebia Therapeutics does not currently pay dividends.
          What is Akebia Therapeutics’s EPS estimate?
          Akebia Therapeutics’s EPS estimate is -$0.15.
            How many shares outstanding does Akebia Therapeutics have?
            Akebia Therapeutics has 184,248,050 shares outstanding.
              What happened to Akebia Therapeutics’s price movement after its last earnings report?
              Akebia Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.183. Following the earnings report the stock price went down -22.33%.
                Which hedge fund is a major shareholder of Akebia Therapeutics?
                Among the largest hedge funds holding Akebia Therapeutics’s share is Woodline Partners LP. It holds Akebia Therapeutics’s shares valued at N/A.


                  Akebia Therapeutics Stock Smart Score

                  The Akebia Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Akebia Therapeutics

                  Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.


                  Top 5 ETFs holding AKBA

                  Currently, no data available
                  Please return soon. This page is being updated.
                  Up to five ETFs with an Outperform Smart Score that hold AKBA. The ETFs are listed according to market value of AKBA within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Biora Therapeutics
                  Galera Therapeutics
                  MEI Pharma
                  SAB Biotherapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis